Dual serotonin and noradrenaline reuptake inhibitors: Focus on their differences

International Journal of Psychiatry in Clinical Practice

Volumn 10, Issue SUPPL. 2, 2006, Pages 22-32

  Blier, Pierre ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Antidepressant; Cytochromes; Noradrenaline; Reuptake; Serotonin

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; ANTIDEPRESSANT AGENT; DESVENLAFAXINE; DRUG METABOLITE; DULOXETINE; MILNACIPRAN; NORADRENALIN; SEROTONIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG; VENLAFAXINE;

ARTICLE; BINDING AFFINITY; CARDIOVASCULAR EFFECT; CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL; CONSTIPATION; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG ABSORPTION; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; DRUG OVERDOSE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG TOLERABILITY; DRUG UPTAKE; ELECTROPHYSIOLOGY; HUMAN; HYPERHIDROSIS; INSOMNIA; MENTAL DISEASE; NAUSEA; NEUROTRANSMISSION; NONHUMAN; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; SEROTONINERGIC SYSTEM; SOMNOLENCE; VERTIGO; XEROSTOMIA;

EID: 33646695920     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.1080/13651500600645612     Document Type: Article

References (65)

1. Benveniste H, Huttemeier PC. Microdialysis: theory and application. Prog Neurobiol 1990;35:195-215.
2. Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002;27:699-711.
3. Bymaster FP, Zhang W, Carter PA, et al. Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology (Berlin) 2002;160:353-61.
4. Wong DT, Bymaster FP. Dual serotonin and noradrenaline uptake inhibitor class of antidepressants potential for greater efficacy or just hype? Prog Drug Res 2002;58:169-222.
5. Invernizzi RW, Garattini S. Role of presynaptic alpha2-adrenoceptors in antidepressant action: Recent findings from microdialysis studies. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:819-27.
6. Moret C, Marien M. Effects of venlafaxine on extracellular levels of 5-HT and noradrenaline in guinea pig hypothalamus. Soc Neurosci Abstr 1997;23:1225-5.
7. Moret C, Briley M. Effects of milnacipran and pindolol on extracellular noradrenaline and serotonin levels in guinea pig hypothalamus. J Neurochem 1997;69:815-22.
8. David DJ, Bourin M, Jego G, Przybylski C, Jolliet P, Gardier AM. Effects of acute treatment with paroxetine, citalopram and venlafaxine in vivo on noradrenaline and serotonin outflow: A microdialysis study in Swiss mice. Br J Pharmacol 2003;140:1128-36.
9. Millan MJ, Gobert A, Lejeune F, et al. S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. J Pharmacol Exp Ther 2001;298:565-80.
10. Weikop P, Kehr J, Scheel-Kruger J. The role of alpha1- and alpha2-adrenoreceptors on venlafaxine-induced elevation of extracellular serotonin, noradrenaline and dopamine levels in the rat prefrontal cortex and hippocampus. J Psychopharmacol 2004;18:395-403.
11. Piacentini MF, Clinckers R, Meeusen R, Sarre S, Ebinger G, Michotte Y. Effects of venlafaxine on extracellular 5-HT, dopamine and noradrenaline in the hippocampus and on peripheral hormone concentrations in the rat in vivo. Life Sci 2003;73:2433-42.
12. Mochizuki D, Tsujita R, Yamada S, et al. Neurochemical and behavioural characterization of milnacipran, a serotonin and noradrenaline reuptake inhibitor in rats. Psychopharmacology (Berlin) 2002;162:323-32.
13. Bel N, Artigas F. Modulation of the extracellular 5-hydroxytryptamine brain concentrations by the serotonin and noradrenaline reuptake inhibitor, milnacipran. Microdialysis studies in rats. Neuropsychopharmacology 1999;21:745-54.
14. Koch S, Hemrick-Luecke SK, Thompson LK, et al. Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats. Neuropharmacology 2003;45:935-44.
15. Kilhara T, Ikeda M. Effects of duloxetine, a new serotonin and norepinephrine uptake inhibitor, on extracellular monoamine levels in rat frontal cortex. J Pharmacol Exp Ther 1995;272:177-83.
16. Gobert A, Rivet JM, Cistarelli JM, et al. Buspirone enhances duloxetine- and fluoxetine-induced increases in dialysate levels of dopamine and noradrenaline, but not serotonin, in the frontal cortex of freely moving rats. J Neurochem 1997;68:1326-9.
17. Engleman EA, Perry KW, Mayle DA, Wong DT. Simultaneous increases of extracellular monoamines in microdialysates from hypothalamus of conscious rats by duloxetine, a dual serotonin and norepinephrine uptake inhibitor. Neuropsychopharmacology 1995;12:287-95.
18. de Montigny C, Wang RY, Reader TA, Aghajanian GK. Monoaminergic denervation of the rat hippocampus: Microiontophoretic studies on pre- and postsynaptic supersensitivity to norepinephrine and serotonin. Brain Res 1980;200:363-76.
19. Pineyro G, Blier P, Dennis T, de Montigny C. Desensitization of the neuronal 5-HT carrier following its long-term blockade. J Neurosci 1994;14:3036-47.
20. Kasamo K, Blier P, de Montigny C. Blockade of the serotonin and norepinephrine uptake processes by duloxetine: in vitro and in vivo studies in the rat brain. J Pharmacol Exp Ther 1996;277:278-86.
21. Béïque J, de Montigny C, Blier P, Debonnel G. Blockade of 5-hydroxytryptamine and noradrenaline uptake by venlafaxine: A comparative study with paroxetine and desipramine. Br J Pharmacol 1998;125:526-32.
22. Curet O, de Montigny C, Blier P. Effect of desipramine and amphetamine on noradrenergic neurotransmission: Electrophysiological studies in the rat brain. Eur J Pharmacol 1992;221:59-70.
23. Béïque JC, de Montigny C, Blier P, Debonnel G. Venlafaxine: Discrepancy between in vivo 5-HT and NE reuptake blockade and affinity for reuptake sites. Synapse 1999;32:198-211.
24. Debonnel G, Saint-André, E, Hébert C, de Montigny C, Lavoie N, Blier P. Differential physiological effects of a low and high doses of venlafaxine in major depression. Int J Neuropsychopharmacol 2006 In press.
25. Clerc GE, Ruimy P, Verdeau-Palles J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group. Int Clin Psychopharmacol 1994;9:139-43.
26. Poirier MF, Boyer P. Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison. Br J Psychiat 1999;175:12-6.
27. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiat 2001;178:234-41.
28. Joubert AF, du Plessis AD, Faries D. High placebo response rate versus clinical impression with the new antidepressant duloxetine. Biol Psychiat 1997;42:S229.
29. Nemeroff CB, Schatzberg AF, Goldstein DJ, et al. Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull 2004;36:106-32.
30. Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and comparative paroxetine-controlled trial. Eur Neuropsychopharmacol 2004;14:457-70.
31. Mongeau R, Weiss M, de Montigny C, Blier P. Effect of acute, short- and long-term milnacipran administration on rat locus coeruleus noradrenergic and dorsal raphe serotonergic neurons. Neuropharmacology 1998;37:905-18.
32. Rueter LE, de Montigny C, Blier P. Electrophysiological characterization of the effect of long-term duloxetine administration on the rat serotonergic and noradrenergic systems. J Pharmacol Exp Ther 1998;285:404-12.
33. Béïque J, de Montigny C, Blier P, Debonnel G. Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine: I. in vivo electrophysiological studies in the rat. Neuropharmacology 2000;39:1800-12.
34. Rueter LE, Kasamo K, de Montigny C, Blier P. Effect of long-term administration of duloxetine on the function of serotonin and noradrenaline terminals in the rat brain. Naunyn-Schmiedeberg's Arch Pharmacol 1998;357:600-10.
35. Béïque JC, de Montigny C, Blier P, Debonnel G. Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine: II. in vitro studies in the rat. Neuropharmacology 2000;39:1813-22.
36. Briley M, Prost JF, Moret C. Preclinical pharmacology of milnacipran. Int Clin Psychopharmacol 1996;11(Suppl 4):9-14.
37. Vis PMJ, van Baardewijk M, Einarson TR. Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: A meta-analysis of randomized clinical trials. Ann Pharmacother 2005;39:1798-807.
38. Perahia D, Pritchett YL, Lee TC, Tran PF. Comparing duloxetine and venlafaxine in the treatment of major depressive disorder using a global benefit-risk approach. New Clinical Drug Evaluation Unit 2005;45:113.
39. Lopez-Ibor J, Guelfi JD, Pletan Y, Tournoux A, Frost JF. Milnacipran and selective serotonin reuptake inhibitors in major depression. Int Clin Psychopharmacol 1996;11(Suppl 4):41-6.
40. Feighner JP. Cardiovascular safety in depressed patients: focus on venlafaxine. J Clin Psychiat 1995;56:574-9.
41. Thase ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry 1998;59:502-8.
42. Khalifa M, Daleau P, Turgeon J. Mechanism of sodium channel block by venlafaxine in guinea pig ventricular myocytes. J Pharmacol Exp Ther 1999;291:280-4.
43. Combes A, Peytavin G, Theron D. Conduction disturbances associated with venlafaxine. Ann Intern Med 2001;134:166-7.
44. Puech A, Montgomery SA, Prost JF, Solles A, Briley M. Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability. Int Clin Psychopharmacol 1997;12:99-108.
45. Montgomery SA, Prost JF, Solles A, Briley M. Efficacy and tolerability of milnacipran: An overview. Int Clin Psychopharmacol 1996;11(Suppl 4):47-51.
46. Schatzberg AF. Efficacy and tolerability of duloxetine, a novel dual reuptake inhibitor, in the treatment of major depressive disorder. J Clin Psychiatry 2003;64(Suppl 13):30-7.
47. Thase ME, Tran PV, Wiltse C, Pangallo BA, Mallinckrodt C, Detke MJ. Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine. J Clin Psychopharmacol 2005;25:132-40.
48. Jick SS, Dean AD, Jick H. Antidepressants and suicide. Br Med J 1995;310:215-8.
49. Buckley NA, McManus PR. Fatal toxicity of serotoninergic and other antidepressant drugs: Analysis of United Kingdom mortality data. Br Med J 2002;325:1332-3.
50. Settle EC J. Antidepressant drugs: Disturbing and potentially dangerous adverse effects. J Clin Psychiatry 1998;59(Suppl 16):25-30.
51. Mazur JE, Doty JD, Krygiel AS. Fatality related to a 30-g venlafaxine overdose. Pharmacotherapy 2003;23:1668-72.
52. Cheeta S, Schifano F, Oyefeso A, Webb L, Ghodse AH. Antidepressant- related deaths and antidepressant prescriptions in England and Wales, 1998-2000. Br J Psychiatry 2004;184:41-7.
53. Mines D, Hill D, Yu H, Novelli L. Prevalence of risk factors for suicide in patients prescribed venlafaxine, fluoxetine, and citalopram. Pharmacoepidemiol Drug Saf 2005;14:367-72.
54. Troy SM, Parker VP, Hicks DR, Pollack GM, Chiang ST. Pharmacokinetics and effect of food on the bioavailability of orally administered venlafaxine. J Clin Pharmacol 1997;37:954-61.
55. Puozzo C, Leonard BE. Pharmacokinetics of milnacipran in comparison with other antidepressants. Int Clin Psychopharmacol 1996;11(Suppl 4):15-27.
56. Lantz RJ, Gillespie TA, Rash TJ, et al. Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. Drug Metab Dispos 2003;31:1142-50.
57. Otton SV, Ball SE, Cheung SW, Inaba T, Rudolph RL, Sellers EM. Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol 1996;41:149-56.
58. Sawada Y, Ohtani H. Pharmacokinetics and drug interactions of antidepressive agents. Nippon Rinsho 2001;59:1539-45.
59. Vaishnavi SN, Nemeroff CB, Plott SJ, Rao SG, Kranzler J, Owens MJ. Milnacipran: A comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry 2004;55:320-2.
60. Stahl SM, Entsuah R, Rudolph RL. Comparative efficacy between venlafaxine and SSRIs: A pooled analysis of patients with depression. Biol Psychiatry 2002;52:1166-74.
61. Entsuah AR, Huang H, Thase ME. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiatry 2001;62:869-77.
62. Goldstein DJ, Lu Y, Detke MJ, Wiltse C, Mallinckrodt C, Demitrack MA. Duloxetine in the treatment of depression: A double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 2004;24:389-99.
63. Kasper S, Pletan Y, Solles A, Tournoux A. Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial results. Int Clin Psychopharmacol 1996;11(Suppl 4):35-9.
64. Goldstein DJ, Mallinckrodt C, Lu Y, Demitrack MA. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry 2002;63:225-31.
65. Nierenberg AA, Greist JH, Mallinckrodt CH, et al. Onset of antidepressant action and acute efficacy and safety of duloxetine versus escitalopram and placebo in the treatment of major depressive disorder. Neuropsychopharmacology 2005;30:S142.